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there is no reason why clearly abnormal results 
on compression ultrasonography would not es-
tablish a firm diagnosis of DVT. Furthermore, in 
a study of the use of negative results on compres-
sion ultrasonography during pregnancy or the 
postpartum period, Le Gal et al.1 found that no 
patient with a negative compression ultrasono-
gram had a thromboembolic event after 3 months 
of follow-up. However, any diagnostic test must 
be interpreted in the clinical context, and if any 
doubt exists, further diagnostic testing should be 
performed.
Dholakia and De Mendonca state that CTPA 
is a better diagnostic tool than ventilation–per-
fusion scanning. We cannot dispute this point 
except to note that many radiology departments 
have a strong preference for one imaging study 
or another, especially for use in pregnant patients. 
A survey of members of the Society of Thoracic 
Radiology reported that 53% perform CTPA as the 
initial study for pregnant women with suspected 
pulmonary embolism, whereas 30% begin with 
ventilation–perfusion scanning.2 Furthermore, re-
cent data involving nonpregnant patients suggest 
that CTPA may be overly sensitive, detecting micro-
emboli that may not be clinically significant.3
Hoftman is correct that the ASRA recommends 
the initiation of low-molecular-weight heparin no 
earlier than 24 hours postoperatively, regardless 
of the anesthetic technique used, and that the first 
dose of low-molecular-weight heparin should be 
delayed for at least 2 hours after an epidural cath-
eter is removed.4 In our practice (and, we assume, 
in the vast majority of obstetric practices), the epi-
dural catheter is removed at the conclusion of a 
cesarean delivery, so that a 24-hour postoperative 
delay in restarting therapeutic low-molecular-
weight heparin is the same as a 24-hour post-
catheter delay. The primary authors of the ASRA 
paper have more recently stated that thrombo-
prophylaxis “should be held until at least 12 hours 
after vaginal delivery or epidural removal (which-
ever is later). After cesarean delivery, thrombopro-
phylaxis should be held for at least 24 hours.”5
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Prevalence of Mitochondrial 1555A→G Mutation  
in European Children
To the Editor: Aminoglycoside antibiotics are 
used worldwide to treat gram-negative sepsis. 
Since these drugs are ototoxic and nephrotoxic, 
drug levels are closely monitored. However, their 
effect on patients with the mitochondrial DNA 
mutation m.1555A→G is dramatic. Carriers of this 
mutation have permanent, profound hearing loss 
after receiving aminoglycosides, even when drug 
levels are within the therapeutic range.1,2 A review 
of previous studies indicates that after aminogly-
coside exposure, penetrance of deafness in this 
population is close to 100%.3
Estimates of the prevalence of the m.1555A→G 
mutation have been hampered because of the 
small numbers of patients in such studies, many 
of which have involved the ascertainment of ei-
ther one or a few patients. We genotyped the 
m.1555A→G variant in the Avon Longitudinal 
Study of Parents and Children (ALSPAC) birth 
cohort, a cohort of children who were not selected 
for hearing loss (www.bristol.ac.uk/alspac).4 Pure-
tone audiometry and tympanometry were per-
formed prospectively in children at ages 7 and 
9 years. Of 9371 children who were tested, 18 had 
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the m.1555A→G mutation, providing a population 
prevalence of 1 in 520, or 0.19% (95% confidence 
interval, 0.10 to 0.28) (for details, see the Supple-
mentary Appendix, available with the full text of 
this letter at NEJM.org). The children with the 
mutation all had hearing thresholds in the clini-
cally normal range at 9 years, indicating that only 
genetic testing could have revealed those at risk 
for deafness (Fig. 1). (See the Supplementary Ap-
pendix for details regarding hearing thresholds 
and tympanometry results for the entire cohort.)
None of the children had a history of admis-
sion to a neonatal intensive care unit, where chil-
dren most commonly receive aminoglycosides. 
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Figure 1. Results of Pure-Tone Audiometry in Children with the m.1555A→G Genotype.
Of 18 children with the m.1555A→G mutation, audiom tric data were available for 14 at the age of 7 years and for  
9 at the age of 9 years. The results of testing of the right ear (Panel A, circles) and the left ear (Panel B, crosses) are 
shown in the 7-year-olds. One of these children had a hearing threshold of 25 to 30 dB at 0.5 to 8 kHz in the right 
ear only. This child had mild eustachian-tube dysfunction on tympanometry. A second child had a slightly raised 
threshold of 25 dB at 500 Hz in the left ear only. At the age of 9 years, both of these children had thresholds of less 
than 20 dB at all frequencies, and all the children who underwent testing had normal hearing thresholds in both 
ears (Panels C and D).
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This finding is consistent with a lack of pene-
trance of the mutation in this cohort.
On the basis of a mutation frequency of 0.19% 
in this population, genetic screening before 
aminoglycoside administration is cost-effective 
when balanced against the costs of lifelong deaf-
ness or the need for cochlear implantation.5 In 
this issue of the Journal, a letter by Vandebona et al.6 
reports a prevalence of 0.21% for the m.1555A→G 
mutation in an aging population of European 
descent, but the prevalence of the mutation in 
non-European populations is unknown. Clearly, 
robust studies involving other ethnic groups are 
required to determine whether screening is ap-
propriate.
On the basis of our findings, we recommend 
that elective genetic testing be performed on a 
case-by-case basis to prevent hearing loss, al-
though in an acute, life-threatening situation, the 
best interests of the patient may require the ad-
ministration of aminoglycosides before the results 
of genetic testing are available. Children with leu-
kemia and patients with tuberculosis could be 
tested at diagnosis, and those allergic to beta-
lactam antibiotics could be tested in the surgical 
outpatient department. Universal screening of neo-
nates would not be effective in preventing 100% 
of deafness related to m.1555A→G, since admis-
sion to a neonatal intensive care unit usually oc-
curs before such screening could take place. 
Screening all pregnant women for the mutation 
would be an alternative approach, since the mu-
tation is maternally inherited and is almost al-
ways homoplasmic. Such an approach would not 
detect low levels of heteroplasmy.
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Prevalence of Mitochondrial 1555A→G Mutation  
in Adults of European Descent
To the Editor: Sensorineural hearing loss is the 
most common type of sensory impairment world-
wide.1 We have found that pathogenic mitochon-
drial DNA (mtDNA) mutations, such as the 
m.3243A→G mutation associated with mitochon-
drial encephalopathy, lactic acidosis, and stroke-
like episodes (MELAS), are prevalent and can 
cause sensorineural hearing loss in adults of Eu-
ropean descent.2 Polymorphisms within mtDNA 
can modify a patient’s risk of hearing loss.3 The 
m.1555A→G mutation, which is located in the 12S 
ribosomal RNA gene of the mitochondrial ge-
nome, is known to cause hearing loss, especially 
after exposure to aminoglycoside antibiotics.4
We prospectively collected audiologic data 
and DNA from blood and hair-follicle samples 
from 2856 subjects over the age of 49 years who 
were noninstitutionalized permanent residents 
of two suburban areas west of Sydney (known 
as the Blue Mountains Hearing Study cohort)2 
and screened them for the m.1555A→G muta-
tion, using polymerase-chain-reaction–restriction-
fragment–length polymorphism techniques. We 
also carried out mitochondrial DNA haplogroup 
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